Red Light Holland's Wholly Owned Subsidiary, Filament Health, Signs Agreement to Supply PEX010 Botanical Psilocybin Drug Candidate for Military Veterans PTSD Study at ARQ National Psychotrauma Centre
Rhea-AI Summary
Red Light Holland (OTCQB: TRUFF) announced that wholly owned subsidiary Filament Health signed an agreement with ARQ National Psychotrauma Centre in the Netherlands to supply its patented botanical psilocybin drug candidate PEX010 for a pilot feasibility study in military veterans with posttraumatic stress disorder (PTSD).
PEX010 will serve as the investigational drug product. According to Red Light Holland, PEX010 has been supplied to more than 80 academic and clinical studies worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.
Positive
- Filament to supply PEX010 for ARQ veterans PTSD feasibility study
- Agreement supports clinical research in military veterans with posttraumatic stress disorder
- PEX010 has been supplied to more than 80 studies worldwide
- Red Light Holland expands pharmaceutical-grade, regulatory and clinical capabilities via Filament
Negative
- None.
News Market Reaction – TRUFF
In the Jul 7 session, TRUFF declined 6.64%, reflecting a notable negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Toronto, Ontario--(Newsfile Corp. - July 7, 2026) - Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) ("Red Light Holland", "Red Light", or the "Company") is an Ontario based organization advancing innovation and research within the legal psychedelic sector. Following its acquisition of Filament Health Corp. ("Filament"), the Company has expanded its pharmaceutical grade manufacturing, regulatory, and clinical research capabilities, supporting the advancement of naturally derived psilocybin development and Filament's patented botanical drug candidate, PEX010.
The Company is pleased to announce that Filament has signed an agreement with ARQ National Psychotrauma Centre ("ARQ"), a leading mental healthcare institute in the Netherlands focused on the treatment of psychotrauma related disorders, to supply PEX010 in support of an academic clinical study titled "Psilocybin-Assisted Psychotherapy for Posttraumatic Stress Disorder in Military Veterans: A Pilot Feasibility Study."
The study is a pilot feasibility study examining psilocybin-assisted psychotherapy in military veterans living with posttraumatic stress disorder. PEX010 will be supplied as the investigational drug product for the study. Research of this kind, conducted within a highly specialised psychotrauma treatment setting, supports a patient population for whom existing treatments often fall short and reflects a long standing clinical commitment to those affected by trauma sustained in service.
PEX010 has now been supplied to more than 80 academic and clinical studies worldwide, making it the natural psilocybin drug candidate of choice for leading research institutions and one of the most widely studied botanical psilocybin drug candidates in regulated clinical research.
"Veteran suicide is something that breaks my heart. These are people who give so much to protect their countries and protect our freedoms, and helping Veterans has always been a personal priority for me," said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland. "Being able to support this study with a reliable supply of PEX010 is something we are very proud of, and I am hopeful that it can lead to wider opportunities to increase access to PEX010 for Veterans and the clinicians working to give them new and effective options."
About Red Light Holland
Red Light is an Ontario based organization advancing a focused strategy within the legal psychedelic sector, centered on consensual data collection and R&D initiatives designed to expand naturally occurring drug development, understanding of psilocybin use and consumer experiences. In parallel, the Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands' legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws.
About Filament Health
Filament Health is a clinical stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first ever natural psychedelic drug candidates.
About ARQ National Psychotrauma Centre
ARQ National Psychotrauma Centre, based in Diemen, the Netherlands, is the country's leading institute in the field of psychotrauma, bringing prevention, diagnosis, treatment, scientific research, and education together under one roof. Its specialised treatment centre, ARQ Centrum '45, provides highly specialised diagnostics and treatment for people with complex and treatment-resistant psychotrauma symptoms, including military veterans, and has a long history of developing innovative therapies for this population.
For additional information on Red Light:
Todd Shapiro
Chief Executive Officer & Director
Tel: 647-204-7129
Email: todd@redlight.co
Website: www.RedLight.co
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain "forward-looking information" within the meaning of applicable Canadian securities legislation. Such forward-looking information and forward-looking statements are not representative of historical facts or information or current conditions but instead represent only the Company's beliefs regarding future events, plans or objectives, many of which, by their nature, are inherently uncertain and outside of the Company's control. Often, but not always, forward-looking statements and information can be identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "estimates", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will" be taken, occur or be achieved. Examples of such information include statements with respect to: the agreement with ARQ National Psychotrauma Centre and the anticipated supply of PEX010 thereunder; the conduct and progress of the referenced military veterans PTSD pilot feasibility study; the expected demand for standardized, naturally derived psilocybin; the recently completed acquisition of Filament Health and the expected integration of Filament's clinical infrastructure and intellectual property; and the future development, commercialization, and regulatory approval of PEX010.
Forward-looking information in this news release is based on certain assumptions and expected future events, namely: the continued ability of Filament to supply PEX010; the performance by ARQ National Psychotrauma Centre and the Company of their respective obligations under the agreement; the successful integration of Filament Health following the completed acquisition; the ability to obtain and maintain any required regulatory permits and approvals, including import and export authorizations; and general business, market and economic conditions. Risks, uncertainties and other factors involved with forward-looking information could cause actual events, results, performance, prospects and opportunities to differ materially from those expressed or implied by such forward-looking information, namely: regulatory or enforcement developments affecting the legal framework for psilocybin supply and research; the risk that integration of Filament Health is not completed as anticipated; the risk that anticipated supply under the agreement does not materialize as expected; delays in regulatory permitting, including import and export authorizations; and adverse changes in the regulatory or political landscape affecting psychedelic research and access.
Although the Company believes that the assumptions and factors used in preparing, and the expectations contained in, the forward-looking information and statements are reasonable, undue reliance should not be placed on such information and statements, and no assurance or guarantee can be given that such forward-looking information and statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information and statements. The forward-looking information and forward-looking statements contained in this press release are made as of the date of this press release, and the Company does not undertake to update any forward-looking information and/or forward-looking statements that are contained or referenced herein, except in accordance with applicable securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/304229